Aespira Ltd. is an inhaler product company which is setting a new standard for single-use disposable dry-powder inhalers (DPIs). 

The company is developing a pipeline of novel inhaler products using generic drugs, addressing new market niches in a unique manner.   In parallel, Aespira will enable pharma companies in the inhaled field to re-position their drugs using Aespira’s foolproof line of inhaler devices.

The company’s inhalers are especially appropriate for delivery of drugs requiring any or all of the following key features:

• Prevention of contamination and cross-contamination

• Simple use by non-trained patients

• Single-dose and/or non-chronic usage

• Clear audible dose confirmation

• Delivery of combination therapies where the drugs powders are stored separately but delivered together